Advertisement
APRE vs MBRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APRE is a Hold and MBRX is a Hold.
APRE's RSI Oscillator ascending out of oversold territory
The RSI Indicator for APRE moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 48 similar instances when the indicator left oversold territory. In 43 of the 48 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for APRE just turned positive on November 03, 2026. Looking at past instances where APRE's MACD turned positive, the stock continued to rise in 34 of 47 cases over the following month. The odds of a continued upward trend are 72%.
Following a +6.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where APRE advanced for three days, in 150 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
APRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APRE as a result. In 86 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The 10-day moving average for APRE crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APRE entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.169) is normal, around the industry mean (3.498). P/E Ratio (-0.551) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. APRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MBRX saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for MBRX moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 39 similar instances where the indicator exited the overbought zone. In 37 of the 39 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBRX as a result. In 77 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for MBRX entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MBRX's RSI Indicator exited the oversold zone, 37 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for MBRX just turned positive on October 23, 2026. Looking at past instances where MBRX's MACD turned positive, the stock continued to rise in 38 of 41 cases over the following month. The odds of a continued upward trend are 90%.
Following a +5.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBRX advanced for three days, in 176 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
MBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 84 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.306) is normal, around the industry mean (3.498). P/E Ratio (0.596) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MBRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
APRE | MBRX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 38 Fair valued | 84 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 86 | 85 | |
P/E GROWTH RATING 1..100 | 19 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 3 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APRE's Valuation (38) in the null industry is somewhat better than the same rating for MBRX (84) in the Pharmaceuticals Major industry. This means that APRE’s stock grew somewhat faster than MBRX’s over the last 12 months.
APRE's Profit vs Risk Rating (100) in the null industry is in the same range as MBRX (100) in the Pharmaceuticals Major industry. This means that APRE’s stock grew similarly to MBRX’s over the last 12 months.
APRE's SMR Rating (98) in the null industry is in the same range as MBRX (100) in the Pharmaceuticals Major industry. This means that APRE’s stock grew similarly to MBRX’s over the last 12 months.
MBRX's Price Growth Rating (85) in the Pharmaceuticals Major industry is in the same range as APRE (86) in the null industry. This means that MBRX’s stock grew similarly to APRE’s over the last 12 months.
APRE's P/E Growth Rating (19) in the null industry is significantly better than the same rating for MBRX (96) in the Pharmaceuticals Major industry. This means that APRE’s stock grew significantly faster than MBRX’s over the last 12 months.
| APRE | MBRX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 86% |
| Advances ODDS (%) | 9 days ago 75% | 7 days ago 78% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 79% | 1 day ago 86% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 84% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APRE’s FA Score shows that 1 FA rating(s) are green while MBRX’s FA Score has 0 green FA rating(s).
- APRE’s FA Score: 1 green, 4 red.
- MBRX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
APRE’s TA Score shows that 5 TA indicator(s) are bullish while MBRX’s TA Score has 4 bullish TA indicator(s).
- APRE’s TA Score: 5 bullish, 4 bearish.
- MBRX’s TA Score: 4 bullish, 4 bearish.
Price Growth
APRE (@Biotechnology) experienced а -11.56% price change this week, while MBRX (@Biotechnology) price change was -4.26% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
APRE is expected to report earnings on Mar 30, 2027.
MBRX is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
APRE and
Correlation & Price change
A.I.dvisor tells us that APRE and ATOS have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APRE and ATOS's prices will move in lockstep.
| Ticker / NAME | Correlation To APRE | 1D Price Change % | ||
|---|---|---|---|---|
| APRE | 100% | +0.27% | ||
| ATOS - APRE | 32% Poorly correlated | -5.14% | ||
| WVE - APRE | 28% Poorly correlated | +0.29% | ||
| NTLA - APRE | 28% Poorly correlated | +2.15% | ||
| MBRX - APRE | 27% Poorly correlated | +0.50% | ||
| STTK - APRE | 27% Poorly correlated | +4.12% | ||
More | ||||
MBRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBRX has been loosely correlated with EDSA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if MBRX jumps, then EDSA could also see price increases.
| Ticker / NAME | Correlation To MBRX | 1D Price Change % | ||
|---|---|---|---|---|
| MBRX | 100% | +0.50% | ||
| EDSA - MBRX | 38% Loosely correlated | +9.90% | ||
| AMRN - MBRX | 32% Poorly correlated | -0.34% | ||
| UNCY - MBRX | 31% Poorly correlated | +3.28% | ||
| AXON - MBRX | 29% Poorly correlated | +4.26% | ||
| VKTX - MBRX | 29% Poorly correlated | -0.77% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EEMV | 71.69 | 1.13 | +1.60% |
| iShares MSCI Emerging Markets Min Vol Factor ETF (EEMV) | |||
| BCUS | 33.49 | 0.51 | +1.56% |
| Bancreek U.S. Large Cap ETF (BCUS) | |||
| IDUB | 26.83 | 0.34 | +1.28% |
| Aptus International Enhanced Yield (IDUB) | |||
| XRPR | 8.69 | 0.08 | +0.97% |
| REX-Osprey XRP ETF (XRPR) | |||
| CBXY | 23.60 | N/A | N/A |
| Calamos Bitcoin 90 Series Structured Alt Protection ETF - July (CBXY) | |||